Benign hepatocyte line and hepatoma cell lines were used to perform in vitro studies to explore the hepatocyte-based TLR-4/IL-17A signaling and potential therapeutic targets against NASH-HCC transition. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatohepatitis.